About this project / Editorial
About Medicine GHK-Cu, and How the Evidence Is Labelled
An independent editorial digest of the GHK-Cu research record, built so every reader can see at a glance which findings are established, which are limited, what is context, and what is a safety note.
What this site is
Medicine GHK-Cu is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper(II) tripeptide also labelled copper tripeptide-1. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. Every quantitative statement on the site is tied to a numbered citation that resolves to a PubMed, PMC, or journal source on the references page.
Why "medicine" is in the name, not in the claims
The word "medicine" in this site's name is editorial framing, not a service or a claim. It marks the question the digest is organized around, what GHK-Cu has been studied for in the research literature, rather than any assertion that the site offers treatment, consultation, or prescriptions. GHK-Cu has no FDA- or EMA-approved therapeutic indication by any route; topical copper tripeptide-1 is a legal cosmetic ingredient, while injectable and systemic use is unapproved and research-only [2]. Nothing here is a dosing recommendation for any person.
How we label the evidence
This digest is built around a simple, honest grammar: each finding is read for both what it shows and where it stops. Strong, reproducible results, such as the picomolar collagen dose-response [1] and the copper-dependence of matrix remodeling [3], are presented as established. Thin or indirect results, such as the hair data that rests on a 5-ALA + GHK combination and an AHK-Cu analog rather than pure GHK-Cu [7][8], are flagged as limited. Definitional material is context, and regulatory status and formulation cautions are safety notes. We also surface the field's known caveats plainly: the absence of validated human pharmacokinetics, the over-quoted 4,000-gene figure, and the fact that a large share of the foundational literature originates with a single investigator and colleagues [5]. The goal is a reader who finishes a page knowing not just what GHK-Cu did, but how much weight each result can bear.
Why we built it to be read by everyone
Evidence is only useful if it can actually be read. This site is designed so the difference between an established finding and a limited one is legible at a glance and never depends on a single channel: each finding carries a clear label word, a status icon, and a color together, so a reader who cannot distinguish certain colors, or who is reading on a small screen, or who navigates by keyboard alone, loses nothing. That principle, designing for the most-constrained reader first, tends to make a page clearer for everyone, which is exactly what a research digest needs when the underlying literature is as mixed as GHK-Cu's. We correct errors. If a citation does not resolve or a figure is wrong, the contact page is the way to tell us, and we will fix it.